← Back to patent-cliff list
Lonafarnib
Tier C — Watch / tradeLonafarnib
MSD (Merck Sharp & Dohme)
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Ftase
Brand：Zokinvy, ZOKINVY
Indications (approved)：早衰综合征
Regional status
US
Approved
2020-11-20
EU
Approved
2022-07-18
China
-
Japan
Approved
2024-01-18
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Lonafarnib?
Approved indications include: 早衰综合征.
When does the Lonafarnib patent expire?
No public expiry year is available for Lonafarnib yet; this page updates once verified.
How do I get a quote for Lonafarnib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27